Leading the charge in next-generation mRNA technology with cutting-edge research and development.
Based on differentiated platform technology
Based on differentiated platform technology
Based on differentiated platform technology
With over 10 years of mRNA research experience, SML Biopharm® possesses proprietary mRNA sequence design, UTR·Poly(A) optimization, and high-efficiency, low-toxicity LNP delivery technology.
We are developing innovative pipelines including personalized cancer vaccines and infectious disease therapeutics based on mRNA platform technology.
Immune Response Based Therapeutics
Cervical Cancer
Immune Response Based Therapeutics
HNSCC
Immune Response Based Therapeutics
COVID-19
In-vivo Protein Expression Therapeutics
SFTS (Severe Fever with Thrombocytopenia Syndrome)
In-vivo Protein Expression Therapeutics
Sarcopenia
In-vivo Protein Expression Therapeutics
Solid Cancer
Cha Vaccine Research Institute and SML BioPharm have signed an MOU for the joint development of mRNA-based vaccines and therapeutics, aiming to establish new pipelines, including cancer vaccines, and an efficient development model.
A research team led by Professor Nam Jae-hwan from Catholic University has published their findings in an international journal, detailing the development of a personalized mRNA cancer vaccine in collaboration with SML Biopharm and confirming its anti-cancer effects in animal models.
SML BioPharm is accelerating the development of therapies for infectious diseases and cancer through its highly stable mRNA design and AI-based LNP platform, with its main pipeline focused on developing a treatment for Severe Fever with Thrombocytopenia Syndrome (SFTS).
We collaborate with leading companies, research institutions, and governments worldwide to develop innovative therapeutics.
If you are interested in R&D collaboration, please contact us.
